Previous 10 | Next 10 |
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which is estimated to increase to around 13.8 million by 2060. W...
Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA). Beginning in August 2021, the Company was the...
Summary BioVie recently presented one of the best cognition improvements ever reported in an open label study in Alzheimer’s disease. Further reporting and biomarkers confirmed those improvements, making BioVie a serious contender in the Alzheimer’s space. A Phas...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimer’s disease ( AD ) drug, simufilam. The trial...
Cassava Sciences ( NASDAQ: SAVA ) has begun an open-label extension study of its Alzheimer's disease candidate simufilam that will last a year. The trial is expected to enroll ~1.6K participants. Enrollment is set to begin in November. The study is for participants...
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll 52-week Study of Simufilam 100 mg Up to 1,600 Patients Are Expected to Enroll AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Na...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, financial traders might forget that Cassava Sciences (NASDAQ: SAVA ) stock is, as the company’s name suggests, all about the science. That’s because the media will distract you with repor...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences (NASDAQ: SAVA ) stock took off once again during September. Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech firm resulted in a bi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ). As the biopharm...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-0.13% Change Percent:
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
Cassava Sciences Inc. Website:
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...